A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma

Trial Profile

A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (Temsr) Regimens In Subjects With Relapsed, Refractory Mantle Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Oct 2017 to 15 Jun 2018.
    • 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Dec 2016 Results (n=90) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top